Literature DB >> 24581524

Prostate cancer antigen 3: diagnostic outcomes in men presenting with urinary prostate cancer antigen 3 scores ≥100.

Fritz H Schröder1, Lionne D F Venderbos2, Roderick C N van den Bergh2, Daphne Hessels3, Geert J L H van Leenders4, Pim J van Leeuwen2, Tineke Wolters2, Jelle O Barentsz5, Monique J Roobol2.   

Abstract

OBJECTIVE: To describe the results of 3 rounds of diagnostic testing and linkage to the Dutch Cancer Registry for men with an initial prostate cancer antigen 3 (PCA3) score ≥100.
METHODS: Within an earlier reported comparative study of PCA3 vs prostate-specific antigen in a prescreened population, 90 men with a PCA3 score ≥100 were identified and underwent biopsy, 28 prostate cancers (PCs) were found, 62 men remained at risk of a diagnosis of PC. All men were offered repeat testing; 6 PCs were found in 20 men at rebiopsy. Men with at least 1 negative biopsy (n = 56) were invited to undergo magnetic resonance imaging (MRI) studies and MRI-guided biopsies if indicated. Linkage to the Dutch Cancer Registry after 2.8 years of follow-up was performed for men with negative biopsies.
RESULTS: Of the 56 men at risk, 28 agreed to participate in further testing. They were offered MRI studies; only 7 men agreed, and in 2, suspicious lesions were found and biopsies carried out. Only 1 PC was diagnosed and classified as T1c, Gleason 3 + 3 = 6. The overall findings of 3 rounds of testing and of linkage to the cancer registry show that eventually 35 PCs were detected in 90 men with PCA3 scores ≥100 (positive predictive value 38.9%).
CONCLUSION: Finding no PC despite extended diagnostic efforts in many men with initial PCA3 scores ≥100 is unexpected and might be clinically relevant.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24581524     DOI: 10.1016/j.urology.2013.12.005

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  6 in total

Review 1.  Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers.

Authors:  Xavier Filella; Laura Foj
Journal:  Int J Mol Sci       Date:  2016-10-26       Impact factor: 5.923

Review 2.  Biomarkers for prostate cancer: present challenges and future opportunities.

Authors:  Pranav Sharma; Kamran Zargar-Shoshtari; Julio M Pow-Sang
Journal:  Future Sci OA       Date:  2015-12-17

3.  Evaluation of a short RNA within Prostate Cancer Gene 3 in the predictive role for future cancer using non-malignant prostate biopsies.

Authors:  Karl H Pang; Derek J Rosario; Susan L Morgan; James W F Catto
Journal:  PLoS One       Date:  2017-04-05       Impact factor: 3.240

Review 4.  Emerging biomarkers in the diagnosis of prostate cancer.

Authors:  Xavier Filella; Esther Fernández-Galan; Rosa Fernández Bonifacio; Laura Foj
Journal:  Pharmgenomics Pers Med       Date:  2018-05-16

Review 5.  Markers of Toxicity and Response to Radiation Therapy in Patients With Prostate Cancer.

Authors:  Nicola J Nasser; Jonathan Klein; Abed Agbarya
Journal:  Adv Radiat Oncol       Date:  2020-10-27

Review 6.  The Role and Significance of Bioumoral Markers in Prostate Cancer.

Authors:  Traian Constantin; Diana Alexandra Savu; Ștefana Bucur; Gabriel Predoiu; Maria Magdalena Constantin; Viorel Jinga
Journal:  Cancers (Basel)       Date:  2021-11-25       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.